



Microbial Characterization of Patients with Community-Acquired Pneumonia by Targeted Next-Generation Sequencing Technology

Han Wang¹, Guoqiang Xing¹, Congying Zhai^{1,*}

¹ Zibo First Hospital, Shandong, China

*Corresponding Author: Department of Pulmonary and Critical Care Medicine, Zibo First Hospital, Zibo, Shandong, China. Email: zhaicongying-02@163.com

Received: 14 February, 2025; Revised: 7 June, 2025; Accepted: 3 July, 2025

Abstract

Background: Community-acquired pneumonia (CAP) has a complex and regionally varying pathogen distribution, and traditional testing methods may underestimate mixed infections and difficult-to-cultivate pathogens.

Objectives: In this study, we analyzed the microbial characteristics of bronchoalveolar lavage fluid (BALF) from CAP patients using targeted next-generation sequencing (tNGS) to provide a basis for optimizing pathogenic diagnosis and individualized treatment.

Methods: A retrospective analysis was conducted on clinical data from 50 CAP patients admitted to Zibo First Hospital in 2024. Patient information collected included baseline characteristics, laboratory findings, and imaging data [Computed Tomography (CT)]. Chi-square analysis, Mann-Whitney U test, and stepwise regression were used to evaluate associations between clinical features and microbial characterization.

Results: Among the 50 CAP patients, 15 (30%) were female and 35 (70%) were male. *Klebsiella pneumoniae* (n = 15), Epstein-Barr virus (EBV) (n = 14), and *Candida albicans* (n = 14) were among the most frequently detected microorganisms. Strong collinearity ($R > 0.80$, $P < 0.05$) was observed between the following microbial pairs: *Proteus mirabilis* and *Serratia marcescens*, enterovirus D68 and *Streptococcus pneumoniae*, *Aspergillus versicolor* and *Moraxella catarrhalis*, *Haemophilus influenzae* and *S. intermedius*. Female patients exhibited a significantly higher rate of *Staphylococcus aureus* infection compared to male patients ($U = 192.50$, $z = -3.15$, $P = 0.002$). Regression analysis indicated that patient age had a significant positive effect on the diversity of microbial infections ($\beta = 0.052$, $t = 3.948$, $P < 0.001$).

Conclusions: *Klebsiella pneumoniae*, EBV, and *C. albicans* may play important roles in CAP. Older CAP patients are more likely to harbor a broader spectrum of viral and fungal pathogens, highlighting the need for heightened clinical attention in this population.

Keywords: Community-Acquired Pneumonia, Targeted Next-Generation Sequencing, Bronchoalveolar Lavage Fluid, Microorganism

1. Background

Community-acquired pneumonia (CAP) is an acute disease caused by an infection of the lung parenchyma acquired outside of a hospital setting. It is one of the leading causes of morbidity and mortality in both immunocompetent and immunocompromised individuals. Determining the severity of the disease and detecting the pathogen are crucial for the outcome of the disease (1). The most common pathogens in CAP include *Streptococcus pneumoniae*, respiratory viruses,

Haemophilus influenzae, *Klebsiella pneumoniae*, *Mycoplasma pneumoniae*, and *Legionella pneumophila* (2, 3). Existing fragmented research suggests that CAP incidence is influenced by various factors such as individual characteristics (age, gender, nutritional status, underlying diseases), environmental factors (region, season, weather, air pollutants), and behavioral factors (smoking, alcohol use, prior antibiotic use) (4).

A study in the United States reports an overall CAP incidence of 16 - 23/1000 person-years (5). The CAP incidence is relatively high and exhibits seasonal

variation, with higher rates in the spring and winter. Moreover, CAP incidence has been rising annually (6). Worldwide, the incidence of CAP is generally higher in men than in women, and it increases with age, particularly among the elderly (6). Understanding the relationship between specific clinical features and microorganisms in CAP patients can significantly improve early diagnostic capability and aid in the development of personalized treatment plans. Accurate identification of the pathogen is key in the diagnosis of CAP (7). Traditional microbiologic testing methods, including bacterial culture, serologic testing, and molecular biology techniques (e.g., PCR) (8), have limitations in detecting microorganisms that are mixed infections, atypical pathogens, or difficult to culture, such as the inability to detect anaerobes. It has been shown that anaerobes may be underestimated pathogens in patients with CAP (9). While these methods can help identify common pathogens, they have limitations, especially in detecting mixed infections, atypical pathogens, or microbes that are difficult to culture.

The use of targeted next-generation sequencing (tNGS) on bronchoalveolar lavage fluid (BALF) has increasingly demonstrated its advantages (10-12). The tNGS allows comprehensive detection of all microorganisms in lung samples, including bacteria, viruses, fungi, and other pathogens, without pre-specifying the pathogen type. This makes it particularly advantageous for diagnosing complex, mixed infections and hard-to-culture pathogens (13). Compared to traditional methods, tNGS offers higher sensitivity and specificity, especially in detecting low-abundance pathogens (14). However, the high cost of tNGS, the complexity of data interpretation, and challenges in interpreting commensal microbes still pose limitations for its routine clinical application (15). Therefore, tNGS is especially useful for diagnosing difficult cases and multiple infections, and with technological advances, its clinical application holds significant promise.

2. Objectives

This study aims to precisely identify high-risk populations and pathogens by comprehensively analyzing the statistical relationship between CAP patients' baseline characteristics, laboratory results, imaging data, and microorganisms, providing new insights into pathogen resistance research and driving the development of resistance management and personalized treatment strategies. This research provides valuable data support for epidemiological and public health fields.

3. Methods

3.1. Sample Collection

This study was conducted at Zibo First Hospital. Clinical data from 50 CAP patients treated between January and December 2024 were retrospectively analyzed. Information was collected using Excel software, with two healthcare providers independently collecting and cross-checking data for accuracy.

3.2. Inclusion and Exclusion Criteria

The diagnosis was based on the "Chinese Adult Community-Acquired Pneumonia Diagnosis and Treatment Guidelines (2016 Edition)" (16) and the "Infectious Diseases Society of America/American Thoracic Society Community-Acquired Pneumonia Guidelines" (17). The specific diagnostic criteria for CAP included: (1) Community onset, with symptoms presenting within 10 days prior to medical consultation; (2) clinical manifestations meeting at least one of the following: Fever, cough, sputum production, or exacerbation of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, shortness of breath, or hemoptysis; lung consolidation signs and/or the presence of rales; peripheral blood white blood cell count $> 10 \times 10^9$ or $< 4 \times 10^9$, with or without a left shift in the neutrophil count; (3) Chest imaging showing newly appeared patchy infiltrates, lobar or segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion. Exclusion criteria included immunosuppressive conditions or immunodeficiency-related gene defects, such as malignancies, organ transplants, HIV infection, or continuous use of immunosuppressive agents within the previous 30 days; non-infectious pneumonia, including pulmonary tuberculosis, lung cancer, non-infectious interstitial lung disease, pulmonary edema, atelectasis, pulmonary embolism, eosinophilic pneumonia, and vasculitis.

3.3. Clinical Data Collection

Direct immune-related markers included white blood cell count, neutrophil absolute value/ratio, lymphocyte absolute value/ratio, monocyte absolute value/ratio, eosinophil/ratio, basophil absolute value/ratio, neutrophil/lymphocyte ratio, globulin level, adenosine deaminase (ADA), and procalcitonin (PCT). Baseline information included gender, age, past medical history, temperature, blood pressure, pulse, and respiratory rate. Laboratory data included urinalysis, bronchoscopy lavage fluid culture results, sputum

culture results, blood tests (complete blood count, blood biochemistry, ESR), liver, kidney, and thyroid function, and myocardial markers. Imaging data included chest Computed Tomography (CT) results (64-slice spiral CT, SOMATOM Drive, Siemens Healthineers, Germany).

3.4. Bronchoalveolar Lavage Fluid Collection

The BALF samples were collected following the "Expert Consensus on Pathogen Detection in Bronchoalveolar Lavage Fluid for Pulmonary Infectious Diseases (2017 Edition)" (18). All CAP patients provided informed consent prior to the procedure. After selecting the lavage lung segment, patients underwent local anesthesia with 2% lidocaine and received multiple (20 - 50 mL) injections of room-temperature sterile saline for lavage, with negative pressure aspiration to collect the BALF in sterile containers. The samples were sent for traditional microbiological testing and mNGS.

3.5. Bronchoalveolar Lavage Fluid High-Throughput Sequencing

Before nucleic acid extraction, samples were inactivated. The library was prepared by fragmenting DNA, repairing ends, attaching sequencing adapters, and performing PCR amplification, followed by sequencing. Data were quality-controlled (sequencing reads > 50 bp and > 20M data) and filtered (removal of host sequences) before aligning with microbial databases. Pathogen microorganisms were identified based on unique reads matching the database with > 1% of the total reads (≥ 10 bp). All sample testing was entrusted to KingMed Diagnostics Group Co., Ltd., and primer and kit information is referenced in the article (19). The microbial species that could be identified by the tNGS technique were placed by us in Appendix 1. *Peptostreptococcus micros*, *Fusobacterium nucleatum*, and *S. intermedius* were anaerobes.

3.6. Statistical Analysis

Data were processed and analyzed using SPSS 25.0 software (IBM Corporation, USA). Continuous variables were expressed as mean \pm SD, and categorical variables as N (%). Independent sample *t*-tests were used for inter-group comparisons of continuous variables; chi-square tests were used for categorical variables. Stepwise forward logistic regression was performed to analyze factors associated with microbial species. A *P*-value of < 0.05 was considered statistically significant.

4. Results

4.1. Baseline Information

Among the 50 CAP patients included in the analysis, 15 (30%) were female and 35 (70%) were male. The median age was 67.00 years (range: 49.00 - 76.00), with a median temperature of 36.70°C (range: 36.50 - 37.50), median pulse rate of 86.00 beats/min (range: 79.50 - 98.00), and median respiratory rate of 19.00 breaths/min (range: 18.00 - 21.25). Among 50 patients with CAP, *P. micros* was detected in 9 cases, *F. nucleatum* in 12 cases, and *S. intermedius* in 3 cases. There was no statistically significant difference between the CAP patients infected with anaerobes (*n* = 16) and those not infected with anaerobes (*n* = 34) in terms of age, gender distribution, marital and childbearing histories, smoking history, and alcohol consumption history (*P* > 0.05) (Table 1).

4.2. Microbial Detection Results

The five most frequently detected bacteria were *K. pneumoniae* (*n* = 15), *F. nucleatum* (*n* = 12), *Moraxella catarrhalis* (*n* = 9), *Acinetobacter baumannii* (*n* = 7), and *S. pyogenes* (*n* = 7). The top five frequencies of viruses were Epstein-Barr virus (EBV) (*n* = 14), Cytomegalovirus (CMV) (*n* = 6), and Herpes simplex virus type 1 (HSV-1) (*n* = 5). The highest frequency of occurrence of specific pathogens was *M. pneumoniae* (*n* = 10). The fungi with the highest frequency of occurrence were *Candida albicans* (*n* = 14), *C. parapsilosis* (*n* = 6), and *Pneumocystis jirovecii* (*n* = 6). Microbial detection in all CAP patients is shown in Figure 1C - E. Strong collinearity (*R* > 0.80, *P* < 0.05) was observed between the following microbial pairs: *Proteus mirabilis* and *Serratia marcescens*, enterovirus D68 and *S. pneumoniae*, *Aspergillus versicolor* and *M. catarrhalis*, *H. influenzae* and *S. intermedius* (Figure 1A and B) (Appendix 1 in Supplementary File).

4.3. Microbial and Baseline Differences

Non-parametric tests were employed to assess differences in microbial distribution across variables such as sex and age. A significant difference in *Staphylococcus aureus* abundance was observed between sexes. Female patients exhibited a significantly higher rate of *S. aureus* infection compared to male patients (*U* = 192.50, *z* = -3.15, *P* = 0.002). A history of smoking showed a significant association with the *M. tuberculosis* complex (*U* = 190.00, *z* = -2.54, *P* = 0.011). A history of diabetes was significantly associated with *C. tropicalis* (*U* = 167.00, *z* = -2.14, *P* = 0.032). Surgical history showed a significant difference in the presence of *M. pneumoniae* (*U* = 187.50, *z* = -2.29, *P* = 0.022). Tumor history was significantly associated with *L. pneumophila* (*U* = 111.00, *z*

Table 1. Baseline Information and Anaerobic Infections in Community-Acquired Pneumonia Patients ^a

Variables	Anaerobic Infection		All Patients	P-Value
No (N = 34)	Yes (N = 16)			
Age	64.00 (36.50, 77.80)	71.00 (55.00, 76.00)	67.00 (49.00, 76.00)	0.632
Pulse (beats/min)	85.00 (75.80, 96.50)	90.00 (80.00, 101.00)	86.00 (76.50, 98.00)	0.274
Temperature (°C)	36.50 (36.30, 37.50)	36.75 (36.50, 37.50)	36.70 (36.50, 37.50)	0.228
Respiration (breaths/min)	19.50 (18.00, 21.30)	19.00 (18.00, 22.50)	19.00 (18.00, 21.25)	0.992
Gender				0.427
Female	9 (26.47)	6 (37.50)	15 (30.00)	
Male	25 (73.53)	10 (62.50)	35 (70.00)	
History of smoking				0.551
No	25 (73.53)	13 (81.25)	38 (76.00)	
Yes	9 (26.47)	3 (18.75)	12 (24.00)	
History of drinking alcohol				0.197
No	27 (79.41)	15 (93.75)	42 (84.00)	
Yes	7 (20.59)	1 (6.25)	8 (16.00)	
History of diabetes				0.725
No	27 (79.41)	12 (75.00)	39 (78.00)	
Yes	7 (20.59)	4 (25.00)	11 (22.00)	
History of hypertension				0.567
No	24 (70.59)	10 (62.50)	34 (68.00)	
Yes	10 (29.41)	6 (37.50)	16 (32.00)	
History of surgery				0.427
No	25 (73.53)	10 (62.50)	35 (70.00)	
Yes	9 (26.47)	6 (37.50)	15 (30.00)	
History of tumors				0.507
No	30 (88.24)	13 (81.25)	43 (86.00)	
Yes	4 (11.76)	3 (18.75)	7 (14.00)	

^a Values are expressed as No. (%).

= -2.68, $P = 0.007$), *P. jirovecii* ($U = 96.50$, $z = -2.68$, $P = 0.007$), and *A. fumigatus* ($U = 93.00$, $z = -3.09$, $P = 0.002$).

4.4. Microbial-Immune Marker Associations

To explore microbial-immune associations, we analyzed immune marker differences for microorganisms with a frequency ≥ 9 among CAP patients. *Brevundimonas diminuta* was significantly associated with four immune parameters: Leukocyte count ($P = 0.043$), absolute neutrophil count ($P = 0.029$), neutrophil-to-lymphocyte ratio ($P = 0.011$), and globulin levels ($P = 0.047$). *Mycoplasma pneumoniae* was significantly associated with five immune parameters: Absolute monocyte count ($P = 0.027$), absolute eosinophil count ($P = 0.011$), lymphocyte ratio ($P = 0.016$), eosinophil ratio ($P = 0.019$), and PCT levels ($P = 0.031$). No other microorganisms demonstrated significant associations with immune markers (Table 2).

4.5. Radiological Findings and Microbial Associations

Radiological data collected included pulmonary nodules, pleural effusion, and tracheal stenosis. CAP patients with pulmonary nodules showed a significant association with *B. diminuta* ($\chi^2 = 7.352$, $P = 0.007$). Patients with pleural effusion demonstrated a significant association with *Kodamaea ohmeri* (formerly *C. krusei*) ($\chi^2 = 5.104$, $P = 0.024$) (Table 3).

4.6. Regression Analysis

A stepwise regression analysis was conducted using gender, age, body temperature (°C), pulse (beats/min), and respiratory rate (breaths/min) as independent variables, and the total number of microorganisms as the dependent variable. The final model identified only age as a significant variable with an R-squared value of 0.245, indicating that age accounts for 24.5% of the variation in the total microbial species count. The model




Figure 1. Distribution of microorganisms detected by bronchoalveolar lavage fluid (BALF) in community-acquired pneumonia (CAP) patients: A, fungal covariance; B, viral covariance; C, proportion of CAP patients with only 1 of the categories of bacteria/fungi/viruses/specialized pathogens; D, proportion of CAP patients with ≥ 2 of the categories of bacteria/fungi/viruses/specialized pathogens detected, and E, the CAP patients with 0/3/4 categories; AA, patients infected with bacteria, viruses and specialized pathogens; AB, patients infected with bacteria, viruses and fungi; AC, patients infected with bacteria, specialized pathogens and fungi; AD, patients infected with both bacteria, viruses, specialized pathogens and fungi; AE, patients with no detectable infecting microorganisms.

passed the F-test ($F = 15.589$, $P = 0.000 < 0.05$), confirming its validity (Table 4). The model equation was: Total microorganisms = $0.622 + 0.052 \times \text{age}$. The regression coefficient for age was 0.052 ($t = 3.948$, $P = 0.000 < 0.01$), indicating a significant positive relationship between age and microbial species count. In the regression model, the detection of *Tropheryma whippelii*, Human rhinovirus A, *M. pneumoniae*, and *S. pneumoniae* showed significant negative correlations with patient age (adjusted $R^2 = 0.69$, Durbin-Watson statistic = 2.20 , $P < 0.01$), suggesting younger patients are more susceptible to infections with these pathogens.

5. Discussion

Our study indicates that *K. pneumoniae*, EBV, *M. pneumoniae*, and *C. albicans* are among the most frequently encountered microbes in CAP patients. Gender differences in CAP patients revealed a significant effect on *S. aureus*. Stepwise regression analysis revealed that viral and fungal diversity in CAP patients increases with age, while younger patients showed heightened susceptibility to infections caused by *T. whippelii*, Human

rhinovirus A, *M. pneumoniae*, and *S. pneumoniae*. The EBV is often reactivated in immunocompromised individuals. Goh et al. reported that EBV reactivation is associated with immunosuppression in CAP and correlates with increased morbidity and prolonged ICU stay (20). Huang et al. found that *C. albicans* infections in immunocompromised patients are often co-infected with other pathogens, complicating disease progression (21).

Fusobacterium nucleatum, an anaerobe commonly found in the oral microbiota, is infrequent in CAP but can lead to severe complications, such as necrotizing pneumonia, especially when co-infected with influenza virus (22). Additionally, Alvarez et al. identified *F. nucleatum* in pleural effusion infections, suggesting its potential pathogenic role in certain pulmonary infections (23). However, our study did not find a clear association between *F. nucleatum* and pleural effusions, warranting further research with larger sample sizes. Although anaerobic bacteria are generally uncommon in pulmonary infections, they are relatively frequent in specific conditions such as aspiration pneumonia, lung

Table 2. Differences in Microbiological-Immunological Indicators

Variables	<i>Microcystis aeruginosa</i>			<i>Mycoplasma pneumoniae</i>		
	U	Z	P	U	Z	P
White blood cells	104.50	-2.028	0.043 ^a	121.50	-1.912	0.056
Absolute neutrophils	98.50	-2.178	0.029 ^a	134.50	-1.593	0.111
Absolute lymphocytes	159.00	-0.646	0.518	126.50	-1.788	0.074
Absolute monocytes	143.00	-1.051	0.293	109.00	-2.214	0.027 ^a
Absolute eosinophils	163.50	-0.533	0.594	96.00	-2.533	0.011 ^a
Absolute basophils	170.00	-0.370	0.711	148.50	-1.263	0.207
Neutrophil ratio	128.50	-1.418	0.156	124.00	-1.849	0.064
Lymphocyte ratio	148.50	-0.912	0.362	100.50	-2.420	0.016 ^a
Monocyte ratio	172.00	-0.317	0.752	168.00	-0.778	0.436
Eosinophil ratio	180.50	-0.101	0.919	103.50	-2.351	0.019 ^a
Basophil ratio	171.00	-0.345	0.730	159.50	-0.993	0.321
Neutrophil/lymphocyte ratio	84.50	-2.533	0.011 ^a	120.00	-1.946	0.052
Calcitoninogen	181.50	-0.076	0.939	111.50	-2.158	0.031 ^a
Globulin	106.00	-1.985	0.047 ^a	129.00	-1.725	0.085
ADA	167.00	-0.460	0.646	156.50	-1.097	0.273

Abbreviation: ADA, adenosine deaminase.

^a P < 0.05**Table 3.** Intergroup Differences in Imaging Information and Microbial Data^a

Title	Values	Total	χ ²	P
	Imaging Abnormal	Imaging Normal		
<i>Microcystis aeruginosa</i>			7.352	0.007 ^b
Not detected	25 (96.15)	16 (66.67)		
Detected	1 (3.85)	8 (33.33)		
	No Pleural Effusion	Pleural Effusion Present		
<i>Candida kudri azwaiensis</i> (<i>Candida krönigii</i>)			5.104	0.024 ^c
Not detected	27 (100.00)	19 (82.61)		
Detected	0 (0.00)	4 (17.39)		

^a Values are expressed as No. (%).^b P < 0.01^c P < 0.05

abscesses, necrotizing pneumonia, and empyema (24). Yamasaki et al. used 16S rRNA gene clone library analysis of BALF from CAP patients and found significantly higher detection rates of anaerobes and oral bacteria compared to traditional cultures, suggesting the role of anaerobes in CAP may be underestimated (25).

Fadell et al. observed a declining contribution of anaerobes in aspiration pneumonia due to the increasing prevalence of gram-negative bacilli (26, 27). In contrast, Fernández-Barat maintained that anaerobes remain key pathogens in pneumonia, especially in cases

of oral microbiota imbalance (27). Traditional microbiological methods often fail to detect anaerobes, whereas tNGS provides a powerful tool for identifying and managing these pathogens (28), as demonstrated in a case of severe pneumonia with empyema. In our study, anaerobic infections accounted for 32% of CAP cases, underscoring the need to consider anaerobes in clinical management.

Our results also indicated sex-based differences in *S. aureus* detection among CAP patients, consistent with previous studies. This phenomenon may be attributed

Table 4. Stepwise Regression Analysis Results

Variables	Regression Coefficient (95% CI)	VIF	Tolerance
Constant	58.679 (16.456) ^a	-	-
Whipple's disease	30.845574	1.136	0.88
Virus	6.412 (2.557) ^b	1.159	0.863
Rhinovirus type A	-27.330 (-2.926) ^a	1.083	0.923
<i>Mycoplasma pneumoniae</i>	-24.522 (-4.971) ^a	1.259	0.794
Fungi	5.942 (3.270) ^a	1.164	0.859
<i>Streptococcus pneumoniae</i>	34.83706	1.168	0.856

^a P < 0.05^b P < 0.01

to several factors. One study reported a higher incidence of *S. aureus* infections in male patients, often associated with more severe clinical manifestations, such as increased hospitalization rates and longer lengths of stay (29). Male patients are also more prone to complications such as empyema and lung abscesses.

Sex differences may influence immune responses to *S. aureus*. Some studies suggest that females may exhibit a stronger immune response to *S. aureus* infections, potentially due to hormonal influences (30). While this may lead to more efficient pathogen clearance, it may also increase the risk of immune-mediated complications. Moreover, antibiotic resistance profiles of *S. aureus* may differ between sexes. Studies have shown higher detection rates of methicillin-resistant *S. aureus* (MRSA) in male patients, possibly due to more frequent healthcare exposure and higher antibiotic usage (31). These resistance differences could affect treatment choices and prognosis.

Finally, sex differences may also influence the epidemiology and transmission of *S. aureus*. Research indicates that men are more likely to be carriers, increasing the risk of community and hospital transmission (32). Further research is needed to elucidate these mechanisms to inform personalized treatment and management strategies.

The observed increase in viral and fungal diversity with age in CAP patients may be due to a combination of immunological and environmental factors. Studies show that non-influenza viral infections are more common in older CAP patients and have similar impacts on disease severity and clinical outcomes as influenza viruses (33). Common respiratory viruses in elderly patients, such as RSV and adenovirus, have high infection rates, likely due to immunosenescence. In addition, fungal infections – such as those caused by RSV and adenovirus – are more frequently observed in

older CAP patients, potentially due to compromised immune defenses (34). Rhinovirus A is also frequently detected in adult CAP cases and is associated with respiratory failure and severe clinical outcomes in elderly individuals (35).

This study has several limitations. First, the observational design inherently limits the ability to establish causal relationships between clinical factors and microbial pathogens in CAP patients. Second, data were collected from a single center, which may affect the generalizability of findings to other healthcare settings or populations with different demographic and clinical characteristics. Additionally, the accuracy and completeness of clinical, laboratory, and imaging data depended on medical records, which may contain missing information or variability in clinical practices. Finally, potential sequencing errors associated with NGS and the inability to detect microorganisms below the 100 copies/mL threshold may have impacted the results.

5.1. Conclusions

This study highlights the role of various pathogens in CAP, revealing significant associations between age, gender, and the diversity of microbial species in patients. Our findings underscore the importance of considering patient demographics, such as age and gender, when diagnosing and treating CAP. Further research is needed to explore the mechanisms behind these associations and to optimize patient management.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors' Contribution: H. W. and G. X. were the tied first authors of this study. They co-designed and implemented the primary data collection, performed the data analysis, and co-authored the first draft of the paper. C. Z. was the corresponding author and was responsible for the overall guidance and supervision of the study, provided key academic support, and offered important suggestions and comments during the revision of the paper.

Conflict of Interests Statement: The authors declare no conflict of interest. None of the authors received any financial support that could have influenced the results of this study or the writing of the thesis. None of the authors were involved in any employment relationships or financial interests that could have influenced the conclusions of this thesis during the course of the study. None of the authors hold stock or shares in any company related to the subject matter of this study, nor have they received any consulting fees, speaking fees, or other compensation of any kind. None of the authors have any patents pending or granted, nor are they involved in any patent matters that may give rise to a financial interest as a result of the publication of this paper. None of the authors have any undisclosed unpaid memberships or consultancy relationships with any governmental or non-governmental organisations, advocacy organisations, commercial companies or educational companies. We hereby declare that the above is completely true and accurate. All authors confirm that they do not have any undeclared financial or non-financial conflicts of interest.

Data Availability: The data presented in this study are uploaded during submission file and are openly available for readers upon request.

Ethical Approval: The data in this study were analyzed in a retrospective format, which is one of the situations where the Clinical Trial Registration Code does not have to be provided. The study was approved by the Medical Ethics Committee of Zibo First Hospital (Approval Number: YXLL20240666).

Funding/Support: The present study received no funding/support.

Informed Consent: The data in this study were analysed retrospectively, which is one of the circumstances in which informed consent did not need to be provided.

References

1. Fan G, Zhou Y, Zhou F, Yu Z, Gu X, Zhang X, et al. The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China. *Lancet Reg Health West Pac*. 2024;**42**:100968. [PubMed ID: 38022712]. [PubMed Central ID: PMC10679495]. <https://doi.org/10.1016/j.lanwpc.2023.100968>.
2. Tang HJ, Lai CC, Chao CM. Changing Epidemiology of Respiratory Tract Infection during COVID-19 Pandemic. *Antibiotics (Basel)*. 2022;**11**(3). [PubMed ID: 35326778]. [PubMed Central ID: PMC8944752]. <https://doi.org/10.3390/antibiotics11030315>.
3. Xu J, Xie L. Advances in immune response to pulmonary infection: Nonspecificity, specificity and memory. *Chronic Dis Transl Med*. 2023;**9**(2):71-81. [PubMed ID: 37305110]. [PubMed Central ID: PMC10249196]. <https://doi.org/10.1002/cdt3.71>.
4. Mahendra M, Jayaraj BS, Limaye S, Chaya SK, Dhar R, Mahesh PA. Factors influencing severity of community-acquired pneumonia. *Lung India*. 2018;**35**(4):284-9. [PubMed ID: 29970765]. [PubMed Central ID: PMC6034384]. https://doi.org/10.4103/lungindia.lungindia_334_17.
5. Kabashneh S, Alkassis S, Ali H. Pneumonia Caused by Three Separate Microorganisms Simultaneously in a Patient Infected with Human Immunodeficiency Virus. *Cureus*. 2020;**12**(4). e7804. [PubMed ID: 32467781]. [PubMed Central ID: PMC7249762]. <https://doi.org/10.7759/cureus.7804>.
6. Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Kilpi TM, Jokinen J. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. *PLoS One*. 2017;**12**(3). e0172690. [PubMed ID: 28249015]. [PubMed Central ID: PMC5332024]. <https://doi.org/10.1371/journal.pone.0172690>.
7. Luan Y, Sun Y, Duan S, Zhao P, Bao Z. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. *J Int Med Res*. 2018;**46**(11):4596-604. [PubMed ID: 30027805]. [PubMed Central ID: PMC6259400]. <https://doi.org/10.1177/0300060518786915>.
8. Wang J, Xu H, Wang X, Lan J. Rapid diagnosis of non-tuberculous mycobacterial pulmonary diseases by metagenomic next-generation sequencing in non-referral hospitals. *Front Cell Infect Microbiol*. 2022;**12**:1083497. [PubMed ID: 36760234]. [PubMed Central ID: PMC9902348]. <https://doi.org/10.3389/fcimb.2022.1083497>.
9. Marin-Corral J, Pascual-Guardia S, Amati F, Aliberti S, Masclans JR, Soni N, et al. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. *Chest*. 2021;**159**(1):58-72. [PubMed ID: 32687909]. <https://doi.org/10.1016/j.chest.2020.06.079>.
10. Ji HL, Li XR, Luo JF, Nie CX, Ren HQ, Ge YL, et al. Neglected Mycobacterium Avium Complex Infection in a Patient with Prolonged Pneumonia. *Clin Lab*. 2024;**70**(6). [PubMed ID: 38868891]. <https://doi.org/10.7754/Clin.Lab.2024.240108>.
11. He Y, Fang K, Shi X, Yang D, Zhao L, Yu W, et al. Enhanced DNA and RNA pathogen detection via metagenomic sequencing in patients with pneumonia. *J Transl Med*. 2022;**20**(1):195. [PubMed ID: 35509078]. [PubMed Central ID: PMC9066823]. <https://doi.org/10.1186/s12967-022-03397-5>.
12. Zuo Y, Shen W, Chen G, Liu H, Liu N, Xu T, et al. Prediction of target genes in community-acquired pneumonia based on the bioinformatics method. *J Thorac Dis*. 2023;**15**(5):2694-707. [PubMed ID: 37324088]. [PubMed Central ID: PMC10267904]. <https://doi.org/10.21037/jtd-23-592>.
13. Zhang Y, Chen J, Chen L, Tang W. Epstein-Barr Virus Infection-Associated Facial Swelling: A Case Report. *Cureus*. 2024;**16**(4). e57635. [PubMed ID: 38707004]. [PubMed Central ID: PMC11070203]. <https://doi.org/10.7759/cureus.57635>.

14. Wang D, Zhang L, Cai Z, Liu Y. Diagnosis of Acute Q Fever in a Patient by Using Metagenomic Next-Generation Sequencing: A Case Report. *Infect Drug Resist.* 2023;**16**:1923-30. [PubMed ID: 37025192]. [PubMed Central ID: PMC10072143]. <https://doi.org/10.2147/IDR.S405697>.
15. Chen J, He T, Li X, Wang X, Peng L, Ma L. Metagenomic Next-Generation Sequencing in Diagnosis of a Case of Pneumocystis jirovecii Pneumonia in a Kidney Transplant Recipient and Literature Review. *Infect Drug Resist.* 2020;**13**:2829-36. [PubMed ID: 32884306]. [PubMed Central ID: PMC7431457]. <https://doi.org/10.2147/IDR.S257587>.
16. Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. *Clin Respir J.* 2018;**12**(4):1320-60. [PubMed ID: 28756639]. [PubMed Central ID: PMC7162259]. <https://doi.org/10.1111/crj.12674>.
17. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med.* 2019;**200**(7):e45-67. [PubMed ID: 31573350]. [PubMed Central ID: PMC6812437]. <https://doi.org/10.1164/jrccm.201908-1581ST>.
18. Qu J, Zhou J, Yu Y. [Chinese expert consensus on detection of pathogens in bronchoalveolar lavage for pulmonary infectious diseases]. *Zhonghua jie he he hu xi za zhi.* 40(8). 2017. p. 578-83. zh. <https://doi.org/10.3760/cma.j.issn.1001-0939.2017.08.007>.
19. Yin Y, Zhu P, Guo Y, Li Y, Chen H, Liu J, et al. Enhancing lower respiratory tract infection diagnosis: implementation and clinical assessment of multiplex PCR-based and hybrid capture-based targeted next-generation sequencing. *EBioMedicine.* 2024;**107**:105307. [PubMed ID: 39226681]. [PubMed Central ID: PMC11403251]. <https://doi.org/10.1016/j.ebiom.2024.105307>.
20. Goh C, Burnham KL, Ansari MA, de Cesare M, Golubchik T, Hutton P, et al. Epstein-Barr virus reactivation in sepsis due to community-acquired pneumonia is associated with increased morbidity and an immunosuppressed host transcriptomic endotype. *Sci Rep.* 2020;**10**(1):9838. [PubMed ID: 32555213]. [PubMed Central ID: PMC7299986]. <https://doi.org/10.1038/s41598-020-66713-3>.
21. Huang L, Xu S, Huang Z, Chen Y, Xu N, Xie B. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing. *BMC Pulm Med.* 2023;**23**(1):72. [PubMed ID: 36829171]. [PubMed Central ID: PMC9951498]. <https://doi.org/10.1186/s12890-022-02300-8>.
22. Akagi Fukushima E, Bhargava A. Unusual case of necrotizing pneumonia caused by Fusobacterium nucleatum complicating influenza a virus infection. *Anaerobe.* 2021;**69**:102342. [PubMed ID: 33567343]. <https://doi.org/10.1016/j.anaerobe.2021.102342>.
23. Alvarez Otero J, Mandrekar J, Wolf MJ, Starkey JC, Carmona EM, Dyrhovden R, et al. Pleural space infection microbiology as assessed using a clinical sequencing-based assay: Fusobacterium nucleatum group, Streptococcus intermedius, and other oral normal microbiota are the most common bacteria identified in community-acquired pleural space infections. *J Clin Microbiol.* 2024;**62**(12). e0069424. [PubMed ID: 39584837]. [PubMed Central ID: PMC11633145]. <https://doi.org/10.1128/jcm.00694-24>.
24. Bartlett JG. How important are anaerobic bacteria in aspiration pneumonia: when should they be treated and what is optimal therapy. *Infect Dis Clin North Am.* 2013;**27**(1):149-55. [PubMed ID: 23398871]. <https://doi.org/10.1016/j.idc.2012.11.016>.
25. Yamasaki K, Kawanami T, Yatera K, Fukuda K, Noguchi S, Nagata S, et al. Significance of anaerobes and oral bacteria in community-acquired pneumonia. *PLoS One.* 2013;**8**(5). e63103. [PubMed ID: 23671659]. [PubMed Central ID: PMC3646017]. <https://doi.org/10.1371/journal.pone.0063103>.
26. Fadell F, Saliba R, El-Solh AA. Bacteriology of Aspiration Pneumonia: The Lung Microbiome and the Changing Microbial Etiology. *Semin Respir Crit Care Med.* 2024;**45**(6):626-33. [PubMed ID: 39536943]. <https://doi.org/10.1055/s-0044-1792111>.
27. Fernandez-Barat L, Lopez-Aladid R, Torres A. Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. *EBioMedicine.* 2020;**60**:102995. [PubMed ID: 32950001]. [PubMed Central ID: PMC7492164]. <https://doi.org/10.1016/j.ebiom.2020.102995>.
28. Yu F, Zhang X, Li Y, Gai W, Zheng Y, Cai X. Severe pneumonia with empyema due to multiple anaerobic infections: case report and literature review. *Front Med (Lausanne).* 2024;**11**:1435823. [PubMed ID: 39206173]. [PubMed Central ID: PMC11349742]. <https://doi.org/10.3389/fmed.2024.1435823>.
29. Cilloniz C, Dominedo C, Gabarrus A, Garcia-Vidal C, Becerril J, Tovar D, et al. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. *J Infect.* 2021;**82**(1):76-83. [PubMed ID: 33144192]. <https://doi.org/10.1016/j.jinf.2020.10.032>.
30. Stensen DB, Smabrekke L, Olsen K, Grimnes G, Sivert Nielsen C, Sollid JUE, et al. Circulating sex-steroids and Staphylococcus aureus nasal carriage in a general female population. *Eur J Endocrinol.* 2021;**184**(6):X3. [PubMed ID: 33984833]. [PubMed Central ID: PMC8183638]. <https://doi.org/10.1530/EJE-20-0877e>.
31. Yao Z, Peng Y, Chen X, Bi J, Li Y, Ye X, et al. Healthcare Associated Infections of Methicillin-Resistant Staphylococcus aureus: A Case-Control Study. *PLoS One.* 2015;**10**(10). e0140604. [PubMed ID: 26470023]. [PubMed Central ID: PMC4607165]. <https://doi.org/10.1371/journal.pone.0140604>.
32. Suvarnsit K, Kiratisin P, Bunnag C, Tantilipikorn P. Prevalence of nasal carriage of Staphylococcus aureus in allergic rhinitis patients and healthy controls in Thailand. *Asian Pac J Allergy Immunol.* 2021;**39**(3):163-7. [PubMed ID: 31677614]. <https://doi.org/10.12932/AP-080719-0598>.
33. Zhou F, Wang Y, Liu Y, Liu X, Gu L, Zhang X, et al. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. *Eur Respir J.* 2019;**54**(2). [PubMed ID: 31164430]. <https://doi.org/10.1183/13993003.02406-2018>.
34. Nielsen SM, Kristensen L, Sondergaard A, Handberg KJ, Stenderup J, Nørskov-Lauritsen N. Increased prevalence and altered species composition of filamentous fungi in respiratory specimens from cystic fibrosis patients. *APMIS.* 2014;**122**(10):1007-12. [PubMed ID: 24698301]. <https://doi.org/10.1111/apm.12253>.
35. Aronen M, Viikari L, Kohonen I, Vuorinen T, Hameenaho M, Wuorela M, et al. Respiratory tract virus infections in the elderly with pneumonia. *BMC Geriatr.* 2019;**19**(1):111. [PubMed ID: 30991957]. [PubMed Central ID: PMC6469155]. <https://doi.org/10.1186/s12877-019-1125-z>.